New Frontiers Science Park

The New Frontiers Science Park is a science park in Essex, on a redeveloped research site of GlaxoSmithKline (GSK).

New Frontiers Science Park
PHE Harlow
Location within Essex
Former names	GSK Harlow
General information
Type	Science park, former research centre
Address	Pinnacles Industrial Estate, Harlow, Essex, CM19 5AD
Coordinates	51.7659°N 0.0693°E
Elevation	65 m (213 ft)
Completed	April 1997
Inaugurated	April 1997
Cost	£250m
Client	SmithKline Beecham Pharmaceuticals
Owner	Public Health England
Dimensions
Other dimensions	18.53 hectares

History

Construction

Planning permission for the site was granted in 1994, opening in April 1997.

SmithKline Beecham

Smith, Kline & French had been headquartered in Welwyn Garden City; it merged with Beecham Group in 1989.[1] Smith Kline & French Research had a research site at Welwyn Garden City and another at The Frythe in rural Hertfordshire in the south of Welwyn; in the early 1980s all research was moved out of Welwyn Garden City to The Frythe.

The site was built by SmithKline Beecham, which became GSK in December 2000 when it merged with Glaxo Wellcome. The site was the UK headquarters of SmithKline Beecham; Glaxo had a takeover of Wellcome in 1995. SmithKline Beecham employed 47,000 staff around the world, with 8,200 in the UK. Jan Leschly (a Danish tennis player) was chief executive of SmithKline Beecham from 1994 to 2000. SmithKline Beecham exported £1.2bn of products. In 1998 SmithKline Beecham spent £910m on research, with £330m of that in the UK.

Beecham Pharmaceuticals previously had its Medicinal Research Centre on the site.,[2] where it worked on hypertension and gastrointestinal disease.

The site was visited by the Princess Royal on the afternoon of 3 February 2000,[3] following on in the morning from attending a meeting about the new Basic Skills Agency.

GSK

SmithKline Beecham became GSK. After the merger, a possibility was that the Harlow site would close or Glaxo Wellcome's Glaxo Research Campus in Stevenage would close; at the time of its construction in the early 1990s, Glaxo Stevenage was the largest single construction site in the UK. At the time of the merger, the USA was accounting for 45% of GSK's sales, with 33% in Europe, and 22% in the rest of the world. The company would be the world's largest pharmaceutical company with a market capitalisation of £114bn. GSK was the largest private sector funder of research in the UK.

2012 Summer Olympics

The site was the Official Laboratory Services Provider for the 2012 Summer Olympics; every medallist and 50% of competitors were tested by GSK there. 150 scientists from King's College London and the World Anti-Doping Agency would be there, to take around 6,000 samples. 240 prohibited substances would be tested for, with about 400 samples per day. By April 2017, 29 medals had been stripped from competitors in the 2012 Olympics, with 13 of these from Russia.

Public Health England

Since 2010, the Health Protection Agency had wanted to move scientific staff to the GSK site in Essex. GSK had proposed to move from the site in February 2010.

Public Health England bought the site on 7 July 2017 for £25m. Staff will move to the site in 2021, and it will be fully operational by 2024. PHE is headed by Duncan Selbie.

Structure

It is situated in Essex on the A1169, over which the site has a footbridge.

Heads of site

• Jackie Hunter CBE

See also

• Alderley Park, former site of ICI, later AstraZeneca
• BioCity Nottingham
• Lilly Research Centre

References

1. GSK history
2. New Scientist October 1988
3. Times, 3 February 2000, page 24

External links

• Public Health England